Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Jun 30, 2025
Revenue increased compared with the prior quarter and also rose relative to the same quarter one year earlier. The sequential improvement reversed a decline in the immediately preceding period.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue increased compared with the prior quarter and also rose relative to the same quarter one year earlier. The sequential improvement reversed a decline in the immediately preceding period.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.7B
Revenue reported for this quarter.
Quarter-over-quarter
+21.4%
Change from the immediately preceding quarter.
Year-over-year
+3.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $3.7B | +10.6% |
| Dec 31, 2024 | $3.8B | +10.3% |
| Mar 31, 2025 | $3B | -3.7% |
| Jun 30, 2025 | $3.7B | +3.6% |
Revenue performance
The reported revenue reflects a sequential gain, following a decrease in the prior quarter. On a year-over-year basis, revenue was higher than the same period last year.
Quarterly comparison
Compared with the immediately preceding quarter, revenue moved higher. Versus the same quarter one year earlier, revenue also increased.
What to watch
The filing context does not provide specific commentary on revenue drivers for this quarter.